<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659178</url>
  </required_header>
  <id_info>
    <org_study_id>ILI108621</org_study_id>
    <nct_id>NCT00659178</nct_id>
  </id_info>
  <brief_title>Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer</brief_title>
  <official_title>A Phase I, Dose Escalation Study to Assess the Safety &amp; Biological Activity of Interleukin 18 (SB-485232) Administered by IV Infusion in Combination With Pegylated Liposomal Doxorubicin (Doxil) in Advanced Stage Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify a dose of SB-485232 which is safe, tolerable and&#xD;
      biologically active when used in combination with pegylated liposomal doxorubicin (Doxil) in&#xD;
      patients with epithelial ovarian cancer. This study will use a standard treatment regimen of&#xD;
      pegylated liposomal doxorubicin (Doxil) in combination with rising doses of SB-485232. The&#xD;
      dose selected from this study will be used in a future studies to evaluate the efficacy of&#xD;
      this combination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 18, 2008</start_date>
  <completion_date type="Actual">February 18, 2011</completion_date>
  <primary_completion_date type="Actual">February 18, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of SB-485232/Doxil combination therapy</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biological activity of SB-485232/Doxil combination therapy</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters for SB-485232 and Doxil: AUC(0-t), Cmax, and Cmin</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic biomarker responses</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity (anti-SB-485232 and anti-PEG antibodies)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity (Radiographic tumor assessments and serum CA-125 levels)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Neoplasms, Ovarian</condition>
  <arm_group>
    <arm_group_label>SB-485232 plus pegylated liposomal doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one dose of pegylated liposomal doxorubicin on Day 1 plus two doses of SB-485232 on Day 3 and Day 9 in each cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-485232 (interleukin 18), pegylated liposomal doxorubicin</intervention_name>
    <description>SB-485232 (interleukin 18), pegylated liposomal doxorubicin</description>
    <arm_group_label>SB-485232 plus pegylated liposomal doxorubicin</arm_group_label>
    <other_name>SB-485232 (interleukin 18)</other_name>
    <other_name>pegylated liposomal doxorubicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female, age ≥18 years of age;&#xD;
&#xD;
          2. Histologically confirmed diagnosis of epithelial ovarian, fallopian tube, or primary&#xD;
             peritoneal carcinoma;&#xD;
&#xD;
          3. Candidate to receive pegylated liposomal doxorubicin for treatment of advanced stage&#xD;
             ovarian cancer as per standard of care and in the opinion of the treating principal&#xD;
             investigator;&#xD;
&#xD;
          4. Measurable lesion(s) according to RECIST v1.0;&#xD;
&#xD;
          5. ECOG performance status of 0, 1 or 2;&#xD;
&#xD;
          6. Predicted life expectancy of ≥4 months&#xD;
&#xD;
          7. No chemotherapy, immunotherapy, hormonal therapy, or biological therapy for cancer,&#xD;
             radiotherapy, or surgical procedures (except for minor surgical procedures) within&#xD;
             four weeks before beginning treatment with SB-485232 (six weeks for nitrosoureas and&#xD;
             mitomycin C). Subjects must have recovered from toxicities (incurred as a result of&#xD;
             previous therapy) sufficiently to be entered into a Phase I study;&#xD;
&#xD;
          8. Disease-free period of at least five years from prior malignancies (except for&#xD;
             curatively treated basal and squamous cell carcinomas of the skin and/or carcinoma of&#xD;
             the cervix in situ);&#xD;
&#xD;
          9. Left ventricular ejection fraction (LVEF) ≥50 % as determined by MUGA scan;&#xD;
&#xD;
         10. A signed and dated written informed consent form is obtained from the subject;&#xD;
&#xD;
         11. The subject is able to understand and comply with protocol requirements, timetables,&#xD;
             instructions and protocol-stated restrictions;&#xD;
&#xD;
         12. The subject is likely to maintain good venous blood access for PK and PD sampling&#xD;
             throughout the study;&#xD;
&#xD;
         13. A female is eligible to enter and participate in the study if she is of:&#xD;
             non-childbearing potential (i.e., physiologically incapable of becoming pregnant) or,&#xD;
             childbearing potential, has a negative serum pregnancy test at the screening visit,&#xD;
             and agrees to one of several GSK acceptable contraceptive methods;&#xD;
&#xD;
         14. Adequate organ function defined as: ANC ≥1.5 x 10^9/L; hemoglobin ≥9 g/dL (after&#xD;
             transfusion if needed); platelets ≥75 x 10^9/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal or&#xD;
             autoimmune conditions that in the opinion of the investigator and/or GSK medical&#xD;
             monitor, places the subject at an unacceptable risk as participant in this trial;&#xD;
&#xD;
          2. Any severe concurrent disease or condition, including significant active autoimmune&#xD;
             diseases such as rheumatoid arthritis, which in the judgment of the principal&#xD;
             investigator, would make the subject inappropriate for study participation;&#xD;
&#xD;
          3. History of myocardial infarction, unstable angina, or acute coronary syndrome within&#xD;
             the past six months;&#xD;
&#xD;
          4. The subject has a history of hypersensitivity reactions to a conventional formulation&#xD;
             of doxorubicin HCl or the components of pegylated liposomal doxorubicin;&#xD;
&#xD;
          5. The subject has a history of receiving a total cumulative dosage of doxorubicin HCl&#xD;
             exceeding the currently recommended limit of 550 mg/m^2 or will exceed the 550 mg/m^2&#xD;
             dosage limit during the course of the current study. A subject will also be excluded&#xD;
             if they received a lower cumulative dosage of doxorubicin HCl (i.e., 400 mg/m^2) and&#xD;
             also had prior radiotherapy to the mediastinal area or concomitant therapy with other&#xD;
             potentially cardiotoxic agents such as cyclophosphamide. Prior use of other&#xD;
             anthracyclines or anthracenediones should be included in calculations of total&#xD;
             cumulative doxorubicin HCl dosage;&#xD;
&#xD;
          6. Women who are pregnant or are breast-feeding;&#xD;
&#xD;
          7. Corrected QT interval (QTc) ≥480 msec (average of three measurements to be made at&#xD;
             screening);&#xD;
&#xD;
          8. The subject has diabetes mellitus with poor glycemic control;&#xD;
&#xD;
          9. The subject has a history of human immunodeficiency virus (HIV) or other&#xD;
             immunodeficiency disease;&#xD;
&#xD;
         10. The subject has positive Hepatitis B surface antigen;&#xD;
&#xD;
         11. The subject has a history of a severe infusion-related reaction following treatment&#xD;
             with pegylated liposomal doxorubicin as described in the protocol;&#xD;
&#xD;
         12. The subject has an acute infection or severe or uncontrolled infections requiring&#xD;
             systemic antibiotic therapy;&#xD;
&#xD;
         13. Any serious medical or psychiatric disorder that would interfere with subject safety&#xD;
             or informed consent;&#xD;
&#xD;
         14. Psychological, familial, sociological, or geographical conditions that do not permit&#xD;
             compliance with the protocol;&#xD;
&#xD;
         15. Known leptomeningeal disease or evidence of prior or current metastatic brain disease.&#xD;
             Routine screening with central nervous system (CNS) imaging studies (CT or MRI) is&#xD;
             required only if clinically indicated;&#xD;
&#xD;
         16. Receiving concurrent chemotherapy, immunotherapy, radiotherapy, or investigational&#xD;
             therapy;&#xD;
&#xD;
         17. Oral corticosteroids within 14 days of study entry;&#xD;
&#xD;
         18. History of ventricular arrhythmias requiring drug or device therapy;&#xD;
&#xD;
         19. Any investigational drug within 30 days or five half-lives (whichever is longer)&#xD;
             preceding the first dose of SB-485232;&#xD;
&#xD;
         20. The subject has active signs of a bowel obstruction.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>April 10, 2008</study_first_submitted>
  <study_first_submitted_qc>April 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2008</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Doxil,</keyword>
  <keyword>pegylated liposomal doxorubicin,</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>IL-18,</keyword>
  <keyword>combination study,</keyword>
  <keyword>immunotherapy,</keyword>
  <keyword>cytokine,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>ILI108621</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ILI108621</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ILI108621</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ILI108621</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ILI108621</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ILI108621</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ILI108621</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

